$CTSO
Cytosorbents Corp Stock $ctso

$ctso Overview Financials Valuation SEC Filings Company Website

2012 Q3 Form 10-Q Financial Statement

#000114420412044924 Filed on August 13, 2012

Income Statement

Concept	2012 Q3	2012 Q2	2011 Q2
Revenue	$605.3K	$33.04K	$0.00
YoY Change
Cost Of Revenue	$141.8K	$10.08K	$0.00
YoY Change
Gross Profit	$463.5K	$72.96K	$0.00
YoY Change
Gross Profit Margin	76.57%	220.82%
Selling, General & Admin	$359.6K	$293.2K	$191.8K
YoY Change	-20.08%	52.86%	-40.06%
% of Gross Profit	77.59%	401.83%
Research & Development	$554.3K	$715.8K	$854.8K
YoY Change	-28.94%	-16.27%	144.24%
% of Gross Profit	119.58%	980.99%
Depreciation & Amortization	$10.00K	$10.00K	$20.00K
YoY Change	-50.0%	-50.0%	100.0%
% of Gross Profit	2.16%	13.71%
Operating Expenses	$1.065M	$1.082M	$1.114M
YoY Change	-13.44%	-2.84%	66.29%
Operating Profit	-$601.2K	-$1.010M	-$1.114M
YoY Change	-51.12%	-9.39%
Interest Expense	-$50.80K	-$37.81K	-$227.0K
YoY Change	-89.84%	-83.35%
% of Operating Profit
Other Income/Expense, Net	-$50.80K	-$37.81K	-$227.0K
YoY Change		-83.35%
Pretax Income	-$652.0K	-$1.047M	-$1.341M
YoY Change	-62.31%	-21.91%	97.23%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$652.0K	-$1.047M	-$1.341M
YoY Change	-62.31%	-21.91%	97.23%
Net Earnings / Revenue	-107.7%	-3169.63%
Basic Earnings Per Share
Diluted Earnings Per Share	-$79.46K	-$135.0K	-$210.4K
COMMON SHARES
Basic Shares Outstanding	203.0M shares	194.9M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2012 Q3	2012 Q2	2011 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$2.100M	$1.700M	$3.400M
YoY Change	-8.7%	-50.0%	466.67%
Cash & Equivalents	$2.061M	$1.742M	$3.417M
Short-Term Investments
Other Short-Term Assets	$100.0K	$100.0K	$0.00
YoY Change			-100.0%
Inventory	$600.0K	$535.3K
Prepaid Expenses
Receivables	$100.0K	$0.00
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$2.900M	$2.467M	$3.500M
YoY Change	16.0%	-29.53%	400.0%
LONG-TERM ASSETS
Property, Plant & Equipment	$100.0K	$142.4K	$100.0K
YoY Change	0.0%	42.44%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$300.0K	$287.2K	$300.0K
YoY Change	0.0%	-4.26%	0.0%
Total Long-Term Assets	$400.0K	$429.7K	$400.0K
YoY Change	0.0%	7.42%	33.33%
TOTAL ASSETS
Total Short-Term Assets	$2.900M	$2.467M	$3.500M
Total Long-Term Assets	$400.0K	$429.7K	$400.0K
Total Assets	$3.300M	$2.896M	$3.900M
YoY Change	13.79%	-25.74%	290.0%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$700.0K	$620.8K	$800.0K
YoY Change	-12.5%	-22.39%	0.0%
Accrued Expenses	$400.0K	$500.0K	$600.0K
YoY Change	-33.33%	-16.67%	200.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Long-Term Debt Due	$1.000M	$1.200M
YoY Change	400.0%
Total Short-Term Liabilities	$2.100M	$2.304M	$1.400M
YoY Change	31.25%	64.59%	16.67%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$500.0K
YoY Change	-100.0%	-100.0%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$500.0K
YoY Change	-100.0%	-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.100M	$2.304M	$1.400M
Total Long-Term Liabilities	$0.00	$0.00	$500.0K
Total Liabilities	$2.100M	$2.304M	$1.900M
YoY Change	16.67%	21.28%	58.33%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock		$199.1K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.200M	$592.0K	$1.900M
YoY Change
Total Liabilities & Shareholders Equity	$3.300M	$2.896M	$3.900M
YoY Change	13.79%	-25.74%	290.0%

Cashflow Statement

Concept	2012 Q3	2012 Q2	2011 Q2
OPERATING ACTIVITIES
Net Income	-$652.0K	-$1.047M	-$1.341M
YoY Change	-62.31%	-21.91%	97.23%
Depreciation, Depletion And Amortization	$10.00K	$10.00K	$20.00K
YoY Change	-50.0%	-50.0%	100.0%
Cash From Operating Activities	-$630.0K	-$1.150M	-$1.030M
YoY Change	-42.73%	11.65%	37.33%
INVESTING ACTIVITIES
Capital Expenditures	$10.00K	-$20.00K	-$30.00K
YoY Change	-150.0%	-33.33%	50.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$0.00
YoY Change
Cash From Investing Activities	$10.00K	-$20.00K	-$30.00K
YoY Change	-150.0%	-33.33%	50.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	950.0K	1.100M	2.040M
YoY Change		-46.08%	10100.0%
NET CHANGE
Cash From Operating Activities	-630.0K	-1.150M	-1.030M
Cash From Investing Activities	10.00K	-20.00K	-30.00K
Cash From Financing Activities	950.0K	1.100M	2.040M
Net Change In Cash	330.0K	-70.00K	980.0K
YoY Change	-129.46%	-107.14%	-230.67%
FREE CASH FLOW
Cash From Operating Activities	-$630.0K	-$1.150M	-$1.030M
Capital Expenditures	$10.00K	-$20.00K	-$30.00K
Free Cash Flow	-$640.0K	-$1.130M	-$1.000M
YoY Change	-40.74%	13.0%	36.99%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2012Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	202962314	shares
CY2012Q1	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	700000
CY2012Q1	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	0.15
CY2012Q1	ctso	Common Stock Warrants Term CommonStockWarrantsTerm	P5Y
CY2012Q1	ctso	Debt Instrument Percent Of Principal Amount DebtInstrumentPercentOfPrincipalAmount	0.25	pure
CY2011Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3416525
CY2012Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	146068
CY2012Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	287225
CY2012Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	42000
CY2012Q2	us-gaap	Stockholders Equity StockholdersEquity	591975.00
CY2012Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2012Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	199053098	shares
CY2012Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	22807046	shares
CY2012Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	293338
CY2012Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0
CY2012Q2	us-gaap	Accounts Receivable Net AccountsReceivableNet	43394
CY2012Q2	us-gaap	Liabilities Liabilities	2304252
CY2012Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	620845
CY2012Q2	us-gaap	Development Stage Enterprise Deficit Accumulated During Development Stage DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage	96272569
CY2012Q2	us-gaap	Assets Assets	2896227
CY2012Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.29
CY2012Q2	us-gaap	Inventory Net InventoryNet	535258
CY2012Q2	us-gaap	Assets Noncurrent AssetsNoncurrent	429668
CY2012Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2896227
CY2012Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1741839
CY2012Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	199053098	shares
CY2012Q2	us-gaap	Liabilities Current LiabilitiesCurrent	2304252
CY2012Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	40587184	shares
CY2012Q2	us-gaap	Common Stock Value CommonStockValue	199053
CY2012Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2012Q2	us-gaap	Assets Current AssetsCurrent	2466559
CY2012Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	241920
CY2012Q2	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	1185351
CY2012Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	142443
CY2012Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	96663905
CY2012Q2	ctso	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	498056
CY2012Q2	ctso	Years Of Service YearsOfService	8	Year
CY2012Q2	ctso	Number Of Patents Issued NumberOfPatentsIssued	29	Patent
CY2012Q2	ctso	Share Based Compensation Arrangements By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y8M12D
CY2012Q2	ctso	Share Based Compensation Arrangement By Sharebased Payment Award Nonvested Options Grant Date Fair Value ShareBasedCompensationArrangementBySharebasedPaymentAwardNonvestedOptionsGrantDateFairValue	478000
CY2010Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1055669
CY2011Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	43728
CY2011Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	269994
CY2011Q4	us-gaap	Stockholders Equity StockholdersEquity	318343.00
CY2011Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	276250
CY2011Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	177626058	shares
CY2011Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1527949
CY2011Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	39833438	shares
CY2011Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2011Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	177626058	shares
CY2011Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	238682
CY2011Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0
CY2011Q4	ctso	Share Based Compensation Arrangement By Share Based Payment Award Nonvested Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedOptionsOutstandingNumber	11910000	shares
CY2012Q2	ctso	Convertible Notes Current Unamortized Discount ConvertibleNotesCurrentUnamortizedDiscount	267649
CY2012Q2	ctso	Convertible Notes Noncurrent Unamortized Discount ConvertibleNotesNoncurrentUnamortizedDiscount	0
CY2012Q2	ctso	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding And Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableAggregateIntrinsicValue	1266000
CY2012Q2	ctso	Share Based Compensation Arrangement By Share Based Payment Award Nonvested Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedOptionsOutstandingNumber	11892000	shares
CY2012Q2	ctso	Share Based Compensation Arrangement By Share Based Payment Award Nonvested Options Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedOptionsWeightedAverageGrantDateFairValue	0.051
CY2011Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	36078
CY2011Q4	us-gaap	Liabilities Liabilities	1804199
CY2011Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	675160
CY2011Q4	us-gaap	Development Stage Enterprise Deficit Accumulated During Development Stage DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage	92557542
CY2011Q4	us-gaap	Assets Assets	2122542
CY2011Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.39
CY2011Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	276250
CY2011Q4	us-gaap	Inventory Net InventoryNet	431022
CY2011Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	425061
CY2011Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2122542
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1186653
CY2011Q4	us-gaap	Common Stock Value CommonStockValue	177626
CY2011Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2011Q4	us-gaap	Assets Current AssetsCurrent	1697481
CY2011Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	192340
CY2011Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	294323
CY2011Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	155067
CY2011Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	92696747
CY2011Q4	ctso	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	558466
CY2011Q4	ctso	Convertible Notes Current Unamortized Discount ConvertibleNotesCurrentUnamortizedDiscount	53677
CY2011Q4	ctso	Convertible Notes Noncurrent Unamortized Discount ConvertibleNotesNoncurrentUnamortizedDiscount	508750
	us-gaap	Net Income Loss NetIncomeLoss	-2555766
	us-gaap	Professional Fees ProfessionalFees	166772
	us-gaap	Operating Expenses OperatingExpenses	2242650
	us-gaap	Proceeds From Contributed Capital ProceedsFromContributedCapital	2756860
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-313116
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	461894
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4175337
	ctso	Debt Discount DebtDiscount	1250000
	ctso	Preferred Dividends Accrued Not Yet Paid PreferredDividendsAccruedNotYetPaid	1619571
	ctso	Stock Issued During Period Value Warrants Exercised Cashless StockIssuedDuringPeriodValueWarrantsExercisedCashless
	ctso	Issuance Of Common Shares For Cashless Exercise Of Warrants IssuanceOfCommonSharesForCashlessExerciseOfWarrants	5666616	shares
CY2011Q4	ctso	Share Based Compensation Arrangement By Share Based Payment Award Nonvested Options Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedOptionsWeightedAverageGrantDateFairValue	0.051
CY2011Q4	ctso	Share Based Compensation Arrangements By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y2M12D
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2242650
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	2953
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	114268
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.03
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	882900
	us-gaap	Stock Issued1 StockIssued1	106344
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	29780
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1620559
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-28398
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	178069
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	17065
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	2360856
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-308923
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-2555766
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1613984
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4009813
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-313116
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	11333
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	146319616	shares
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	304167
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	1619571
	us-gaap	Proceeds From Other Debt ProceedsFromOtherDebt	1250000
	dei	Trading Symbol TradingSymbol	CTSO
	dei	Entity Registrant Name EntityRegistrantName	CYTOSORBENTS CORP
	dei	Amendment Flag AmendmentFlag	false
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2012
	dei	Document Type DocumentType	10-Q
	dei	Document Period End Date DocumentPeriodEndDate	2012-06-30
	dei	Entity Central Index Key EntityCentralIndexKey	0001175151
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4532
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2076729
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.008	pure
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.15
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	33.57
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	60581
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.02
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	3951540	shares
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	395153
	us-gaap	Basis Of Accounting BasisOfAccounting	<div style="font: 10pt Times New Roman, Times, Serif"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <b>1.   BASIS OF PRESENTATION</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the requirements of Form 10-Q of the Securities and Exchange Commission (the “Commission”) and include the results of CytoSorbents Corporation (the “Parent”), CytoSorbents, Inc., its wholly-owned operating subsidiary (the “Subsidiary”), and CytoSorbents Europe GmbH, its wholly-owned European subsidiary (the “European Subsidiary”), collectively referred to as “the Company.” Accordingly, certain information and footnote disclosures required in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. Interim statements are subject to possible adjustments in connection with the annual audit of the Company's accounts for the year ended December 31, 2012. In the opinion of the Company’s management, the accompanying unaudited consolidated financial statements contain all adjustments (consisting only of normal recurring adjustments) which the Company considers necessary for the fair presentation of the Company's consolidated financial position as of June 30, 2012 and the results of its operations and cash flows for six and three month periods ended June 30, 2012 and 2011, and for the period January 22, 1997 (date of inception) to June 30, 2012. Results for the six and three months ended are not necessarily indicative of results that may be expected for the entire year. The unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements of the Company and the notes thereto as of and for the year ended December 31, 2011 as included in the Company’s Form 10-K filed with the Commission on March 30, 2012.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company has experienced negative cash flows from operations since inception and has a deficit accumulated during the development stage at June 30, 2012 of $96,272,569. The Company is not currently generating significant revenue and is dependent on the proceeds of present and future financings to fund its research, development and commercialization program. These matters raise substantial doubt about the Company’s ability to continue as a going concern.  The Company is continuing its fund-raising efforts.  Although the Company has historically been successful in raising additional capital through equity and debt financings, there can be no assurance that the Company will be successful in raising additional capital in the future or that it will be on favorable terms.  Furthermore, if the Company is successful in raising the additional financing, there can be no assurance that the amount will be sufficient to complete the Company's plans. These consolidated financial statements do not include any adjustments related to the outcome of this uncertainty.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">  The Company is a development stage company and has not yet generated significant revenues from inception to June 30, 2012. Since inception, the Company's expenses relate primarily to research and development, organizational activities, clinical manufacturing, regulatory compliance and operational strategic planning.  Although the Company has made advances on these matters, there can be no assurance that the Company will continue to be successful regarding these issues, nor can there be any assurance that the Company will successfully implement its long-term strategic plans.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> The Company has developed an intellectual property portfolio, including 29 issued and multiple pending patents, covering materials, methods of production, systems incorporating the technology and multiple medical uses.</p> </div>
	us-gaap	Stock Issued1 StockIssued1	213584
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	102340
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	4532
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2260153
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1065
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	555186
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font: 10pt Times New Roman, Times, Serif"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <b>Concentration of Credit Risk</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> The Company maintains cash balances, at times, with financial institutions in excess of amounts insured by the Federal Deposit Insurance Corporation. Management monitors the soundness of these institutions in an effort to minimize its collection risk of these balances.</p> </div>
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	21415
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2218792
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-26022
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y4M21D
	us-gaap	Dividends Preferred Stock Stock DividendsPreferredStockStock	1241121
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	7316
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-2473906
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1309031
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2800000
	us-gaap	Interest Expense Debt InterestExpenseDebt	235762
	us-gaap	Professional Fees ProfessionalFees	234827
	us-gaap	Operating Expenses OperatingExpenses	2106504
	us-gaap	Proceeds From Contributed Capital ProceedsFromContributedCapital	2100000
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-397177
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.28	pure
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	104236
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	20160
	us-gaap	Revenues Revenues	49935
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4532
	us-gaap	Gross Profit GrossProfit	29775
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	24957
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	187795284	shares
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	382478
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	1241121
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.019	pure
	us-gaap	Proceeds From Other Debt ProceedsFromOtherDebt	700000
	us-gaap	Net Income Loss NetIncomeLoss	-2473906
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-397177
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	562646
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	868000	shares
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3715027
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font: 10pt Times New Roman, Times, Serif"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <b>Use of Estimates</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities. Actual results could differ from these estimates. Significant estimates in these financials are the valuation of options granted, the valuation of preferred shares issued as stock dividends and valuation methods used in determining any debt discount associated with convertible securities.</p> </div>
	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	87700
	ctso	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Granted In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingGrantedInPeriodWeightedAverageRemainingContractualTerm	P4Y9M18D
	ctso	Debt Discount DebtDiscount	87700
	ctso	Preferred Dividends Accrued Not Yet Paid PreferredDividendsAccruedNotYetPaid	1241121
	ctso	Issuance Of Common Stock In Exchange For Convertible Notes Value IssuanceOfCommonStockInExchangeForConvertibleNotesValue	395153
	ctso	Stock Issued During Period Value Warrants Exercised Cashless StockIssuedDuringPeriodValueWarrantsExercisedCashless
	ctso	Issuance Of Common Stock In Exchange For Convertible Notes Shares IssuanceOfCommonStockInExchangeForConvertibleNotesShares	3951540	shares
	ctso	Issuance Of Common Shares For Cashless Exercise Of Warrants IssuanceOfCommonSharesForCashlessExerciseOfWarrants	5666616	shares
	ctso	Share Based Compensation Arrangement By Share Based Payment Award Nonvested Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedOptionsGrantsInPeriod	868000	shares
	ctso	Share Based Compensation Arrangement By Share Based Payment Award Nonvested Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedOptionsVestedInPeriod	886000	shares
	ctso	Share Based Compensation Arrangement By Share Based Payment Award Nonvested Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedOptionsForfeituresInPeriod		shares
	ctso	Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod	114254	shares
	ctso	Share Based Compensation Arrangement By Share Based Payment Award Nonvested Options Granted In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedOptionsGrantedInPeriodWeightedAverageGrantDateFairValue	0.050
	ctso	Share Based Compensation Arrangement By Share Based Payment Award Nonvested Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedOptionsVestedInPeriodWeightedAverageGrantDateFairValue	0.047
	ctso	Share Based Compensation Arrangement By Share Based Payment Award Nonvested Options Forfeited In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedOptionsForfeitedInPeriodWeightedAverageGrantDateFairValue
	ctso	Share Based Compensation Arrangement By Share Based Payment Award Non Vested Options Vested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonVestedOptionsVestedNumber	9957000	shares
	ctso	Voluntarily Employee Termination Date VoluntarilyEmployeeTerminationDate	2012-07-13
	ctso	Position Assumed Effective Date PositionAssumedEffectiveDate	2012-07-16
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	499395
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	3018437
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	32491
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	255882
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	12344602
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4506217
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	361495
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	2509592
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2402025
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	1741839
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	56394
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	417616
	us-gaap	Stock Issued1 StockIssued1	549534
	us-gaap	Other Noncash Expense OtherNoncashExpense	361496
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2470830
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	5141
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-64796201
	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	399395
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	43394
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-87168143
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	52208369
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	71044257
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	1823103
CY2012Q1	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.08	pure
CY2012Q1	ctso	Debt Instrument Maturity Period DebtInstrumentMaturityPeriod	P12M
CY2012Q1	ctso	Warrant Exercise Price WarrantExercisePrice	0.175
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	216617
	us-gaap	Service Management Costs ServiceManagementCosts	1334285
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	393607
	us-gaap	Operating Income Loss OperatingIncomeLoss	-79910629
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	400490
	us-gaap	Professional Fees ProfessionalFees	8192717
	us-gaap	Other Operating Income OtherOperatingIncome	6055483
	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	533648
	us-gaap	Operating Expenses OperatingExpenses	79964722
	us-gaap	Proceeds From Contributed Capital ProceedsFromContributedCapital	48671310
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-7134299
	us-gaap	Paid In Kind Interest PaidInKindInterest	3147
	us-gaap	Payments To Acquire Loans Receivable PaymentsToAcquireLoansReceivable	1632168
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	535258
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	393607
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	31920
	us-gaap	Revenues Revenues	86013
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	21663
	us-gaap	Gross Profit GrossProfit	54093
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	559
	us-gaap	Interest Paid InterestPaid	590189
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	504515
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	2376855
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	9651744
	us-gaap	Proceeds From Other Debt ProceedsFromOtherDebt	11888881
	us-gaap	Net Income Loss NetIncomeLoss	-86620825
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-7257514
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	25619119
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-547318
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-96272569
	us-gaap	Other Amortization Of Deferred Charges OtherAmortizationOfDeferredCharges	74938
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	183556
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	9579040
	ctso	Supplemental Noncash Transactions SupplementalNoncashTransactions	768063
	ctso	Technology And Content Expense TechnologyAndContentExpense	4550000
	ctso	Debt Discount DebtDiscount	1644505
	ctso	Preferred Dividends Accrued Not Yet Paid PreferredDividendsAccruedNotYetPaid	9651744
	ctso	Consulting Fees ConsultingFees	237836
	ctso	Change In Fair Value Of Management Units ChangeInFairValueOfManagementUnits	278087
	ctso	Stock Issued During Period Value Warrants Exercised Cashless StockIssuedDuringPeriodValueWarrantsExercisedCashless
	ctso	Issuance Of Common Shares For Cashless Exercise Of Warrants IssuanceOfCommonSharesForCashlessExerciseOfWarrants	5666616	shares
CY2011Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1114159
CY2011Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.01
CY2011Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-1341182
CY2011Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	854827
CY2011Q2	us-gaap	Professional Fees ProfessionalFees	67530
CY2011Q2	us-gaap	Operating Expenses OperatingExpenses	1114159
CY2011Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-227023
CY2011Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	159137446	shares
CY2011Q2	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	877926
CY2011Q2	us-gaap	Net Income Loss NetIncomeLoss	-1341182
CY2011Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-227023
CY2011Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	191802
CY2011Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2219108
CY2012Q1	us-gaap	Debt Instrument Convertible Beneficial Conversion Feature DebtInstrumentConvertibleBeneficialConversionFeature	48912
CY2012Q1	us-gaap	Proceeds From Other Debt ProceedsFromOtherDebt	700000
CY2012Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1009503
CY2012Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.01
CY2012Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-1047310
CY2012Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	665750
CY2012Q2	us-gaap	Professional Fees ProfessionalFees	73535
CY2012Q2	us-gaap	Operating Expenses OperatingExpenses	1032465
CY2012Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-37807
CY2012Q2	us-gaap	Cost Of Goods Sold CostOfGoodsSold	10080
CY2012Q2	us-gaap	Revenues Revenues	33042
CY2012Q2	us-gaap	Gross Profit GrossProfit	22962
CY2012Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	194439923	shares
CY2012Q2	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	577204
CY2012Q2	us-gaap	Net Income Loss NetIncomeLoss	-1047310
CY2012Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-37807
CY2012Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	293180
CY2012Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1624514

Files In Submission

Name	View Source	Status
0001144204-12-044924-index-headers.html	Edgar Link	pending
0001144204-12-044924-index.html	Edgar Link	pending
0001144204-12-044924.txt	Edgar Link	pending
0001144204-12-044924-xbrl.zip	Edgar Link	pending
ctso-20120630.xml	Edgar Link	completed
ctso-20120630.xsd	Edgar Link	pending
ctso-20120630_cal.xml	Edgar Link	unprocessable
ctso-20120630_def.xml	Edgar Link	unprocessable
ctso-20120630_lab.xml	Edgar Link	unprocessable
ctso-20120630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v318616_10q.htm	Edgar Link	pending
v318616_ex31-1.htm	Edgar Link	pending
v318616_ex31-2.htm	Edgar Link	pending
v318616_ex32-1.htm	Edgar Link	pending
v318616_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CTSO
Cytosorbents Corp Stock $ctso

2012 Q3 Form 10-Q Financial Statement

#000114420412044924 Filed on August 13, 2012

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CTSO Cytosorbents Corp Stock $ctso

2012 Q3 Form 10-Q Financial Statement

#000114420412044924 Filed on August 13, 2012

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CTSO
Cytosorbents Corp Stock $ctso